Stock · MRNA · Healthcare
United States · Large Cap · listed since 2018 · Revenue 12 mo. $2.2B
Price as of 11/06/2026
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Original text from the data provider
Summary
40.0 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
with respect to the priced-in expectation
No indication in the stored figures.
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
2 more unchanged: Revenue, 12 mo., Shares outstanding
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | −32.62% | 11.52% | Rank 7 |
| Return on capital (Greenblatt) | −41.48% | 32.55% | Rank 5 |
| EBIT margin | −158.13% | 18.31% | Rank 2 |
| FCF margin | −106.22% | 14.12% | Rank 2 |
| Gross margin | 55.35% | 60.99% | Rank 42 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | −39.23% | 8.04% | Rank 3 |
| Earnings growth, 3 years per yeardoes not count towards the rank | – | 5.44% | |
| Earnings growth, 5 years per yeardoes not count towards the rank | – | 7.00% | |
| Sustainable growth (ROE × retained earnings) | 9.88% | 3.66% | Rank 92 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | −2.85% | 2.90% | Rank 6 |
| FCF yield | −2.03% | 3.63% | Rank 3 |
| EV/saleslower is better | 50.42 | 4.03 | Rank 2 |
| EV/EBITlower is betterdoes not count towards the rank | – | 21.73 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 935.15% | 8.66% | Rank 100 |
| Share price, 6 months | 368.17% | 24.27% | Rank 100 |
| Share price, 3 months | 334.72% | 15.42% | Rank 100 |
| Distance from 52-week high | −1.62% | −7.35% | Rank 79 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | −21.87% | 0.30% | Rank 99 |
| Change in share countlower is better | 1.30% | 0.00% | Rank 12 |
| Dividend streak in years | – | 10 | Rank 13 |
| Price reaction to results, market-adjusted | −5.54% | 0.05% | Rank 9 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 70.11% | 48.40% | Rank 79 |
| Net debt/EBITDAlower is betterdoes not count towards the rank | – | 1.11 | |
| Debt to equitylower is better | 0.22 | 0.48 | Rank 70 |
| Volatility, 1 yearlower is better | 193.79% | 31.42% | Rank 0 |
Ten years in figures
| Year | Revenue | EBIT margin | FCF | Shares | Net debt |
|---|---|---|---|---|---|
| 2016 | $108.4M | −206.4% | $33.6M | 376M | −$37.6M |
| 2017 | $205.8M | −130.9% | −$389.9M | 376M | −$119.2M |
| 2018 | $122.5M | −337.3% | −$436.6M | 81.1M | −$624.9M |
| 2019 | $48.0M | −1,136.1% | −$490.5M | 331M | −$103.5M |
| 2020 | $274.5M | −278.0% | $2.0B | 381M | −$2.4B |
| 2021 | $17.7B | 75.0% | $13.3B | 431M | −$5.9B |
| 2022 | $18.9B | 49.9% | $4.6B | 416M | −$2.0B |
| 2023 | $6.8B | −61.9% | −$3.8B | 382M | −$1.7B |
| 2024 | $3.2B | −123.3% | −$4.1B | 384M | −$1.2B |
| 2025 | $1.9B | −158.1% | −$2.1B | 389M | −$679.0M |
1 of 7 StockScorer Score rules met · How the score is built
Moderna Inc mainly meets criteria in the Momentum category. Result from 18 strategies checked.
Moderna Inc is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
1 of 7 rules met
1 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Moderna Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | −9.2 | 30.0 |
| P/B ratio | 11.4 | 4.8 |
| Return on equity (ROE) | −32.6% | 11.5% |
| Equity ratio | 70.1% | 48.4% |
| Debt-to-equity (D/E) | 0.22 | 0.48 |
| Dividend yield | 0.0% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| MRNA | Moderna Incthis page | |
| REGN | Regeneron Pharmaceuticals Inc | Medium5.5 |
| VRTX | Vertex Pharmaceuticals Inc | Medium5.5 |
| RVMD | Revolution Medicines Inc | locked |
| RPRX | Royalty Pharma Plc | locked |
| CSL.AX | CSL Ltd | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.